论文信息 - 1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma - 字舞流文

1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma

W. Bechstein | P. Reichardt | R. Hofheinz | S. Al-Batran | M. Ebert | T. Gaiser | D. Pink | M. Welslau | E. Goekkurt | T. Goetze | T. Ettrich | C. Pauligk | A. Kretzschmar | G. Siegler | R. Mahlberg | N. Homann | D. Sookthai | C. Teschendorf | G. Haag | K. Borchert